These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35445305)

  • 1. Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis.
    Yoshida T; Ohe C; Ito K; Takada H; Saito R; Kita Y; Sano T; Tsuta K; Kinoshita H; Kitamura H; Nishiyama H; Kobayashi T;
    Cancer Immunol Immunother; 2022 Nov; 71(11):2815-2828. PubMed ID: 35445305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Chen S; Zhang N; Wang T; Zhang E; Wang X; Zheng J
    Front Immunol; 2020; 11():1900. PubMed ID: 32983112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell atlases link macrophages and CD8
    Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
    Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
    [No Abstract]   [Full Text] [Related]  

  • 5. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
    Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
    Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
    Front Immunol; 2021; 12():634741. PubMed ID: 34220801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Ferro M; Crocetto F; Tataru S; Barone B; Dolce P; Lucarelli G; Sonpavde G; Musi G; Antonelli A; Veccia A; Terracciano D; Busetto GM; Del Giudice F; Marchioni M; Schips L; Porpiglia F; Fiori C; Carrieri G; Lasorsa F; Verde A; Scafuri L; Buonerba C; Di Lorenzo G
    Clin Genitourin Cancer; 2023 Oct; 21(5):574-583. PubMed ID: 37419854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
    Labidi S; Meti N; Barua R; Li M; Riromar J; Jiang DM; Fallah-Rad N; Sridhar SS; Del Rincon SV; Pezo RC; Ferrario C; Cheng S; Sacher AG; Rose AAN
    BMJ Open; 2024 Mar; 14(3):e081480. PubMed ID: 38553056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review.
    Taguchi S; Kawai T; Nakagawa T; Kume H
    Jpn J Clin Oncol; 2024 Mar; 54(3):254-264. PubMed ID: 38109484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8
    Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
    Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.
    Seitz RS; Hurwitz ME; Nielsen TJ; Bailey DB; Varga MG; Ring BZ; Metts CF; Schweitzer BL; McGregor K; Ross DT
    J Transl Med; 2022 Aug; 20(1):370. PubMed ID: 35974414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
    Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
    World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
    Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis.
    Lin CT; Su PJ; Huang SY; Wu CC; Wang HJ; Cheng YT; Luo HL; Chen CH; Liu TT; Huang CC; Su YL
    J Immunother; 2022 Nov-Dec 01; 45(9):407-414. PubMed ID: 36121316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
    Makrakis D; Talukder R; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Jang A; Barata P; Sonpavde G; Yu EY; Montgomery RB; Grivas P; Khaki AR
    Clin Genitourin Cancer; 2022 Oct; 20(5):e440-e452. PubMed ID: 35778337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
    Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
    Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.